北京若生智能科技有限公司
Drug Database
IV

IVIG (Privigen / IVIG, liquid, CSL / IgPro10)

✓ Approved

CSL Behring · 多克隆抗体 · 多克隆抗体

什么是 IVIG？

IVIG 是一种多克隆抗体，由CSL Behring研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Privigen, IVIG, liquid, CSL, IgPro10
公司CSL Behring
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, CSL Behring

治疗适应症

IVIG 针对 9 个适应症，涉及 6 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersPurpura✓ Approved
Immune system disordersImmunodeficiency✓ Approved
Nervous system disordersMultifocal motor neuropathy✓ Approved
Musculoskeletal and connective tissue disordersScleroderma✓ Approved
Nervous system disordersGuillain-Barre syndrome✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedInternational journal of technology assessment in health care2026-10-26

A clinical service line investment recovery framework for medical equipment: method specification and a retrospective records-based feasibility application.

Shibuya Takashi T, Kutsuna Nobuo N

Hospitals may not preserve the assumptions approved for medical-equipment purchases alongside post-adoption financial and value outcomes. We specified a clinical service line (CSL) investment recovery framework and examined its initial feasibility using routine hospital records. Targeted mapping of health technology assessment (HTA), lifecycle HTA, management accounting, and organizational learning concepts was followed by internal logic checks. A retrospective records-based application was conducted for one purposively selected 4 K arthroscopy camera-head investment at a Japanese acute-care hospital. Aggregate fixed-asset, lease, and claims records were analyzed descriptively without patient-level data or causal attribution. The framework links CSL definition, pre-adoption commitments, annualized investment burden (AIB), contribution margin (CM), evidence status, allocation, value guardrails, and feedback. The 72-month lease had a total value of JPY 4,728,240 and a minimum documented annual burden of JPY 788,040. Shoulder arthroscopy volume increased from 220 to 245 procedures (11.4 percent), and nominal procedure-fee revenue increased from JPY 102.8 million to JPY 114.9 million (11.8 percent) between 12-month periods. Planned values, variable costs, direct use logs, and prespecified quality or access indicators were unavailable; CM-based recovery metrics could not be calculated. The documented annual burden equaled JPY 31,522 per observed additional procedure, or 6.52 percent of the observed revenue increase under full attribution. The framework operationalizes hospital-level post-adoption and lifecycle HTA as an auditable CSL process. The application demonstrated partial data availability and identified fields that must be preserved prospectively; it did not establish causality, actual recovery, acceptability, or decision impact.

PMID 42929660
阅读全文 →
PubMedBMC cancer2026-10-26

Single-cell transcriptomic atlas of gastric cancer reveals malignant cell heterogeneity and nominates EMB as a candidate prognostic biomarker.

Ma Zheng Z, Huang Na N, Ren Bingjie B, Wang Tianran T et al.

Gastric cancer (GC) shows marked cellular heterogeneity and a complex immune microenvironment, which limits reliable biomarkers and therapeutic targets. We constructed a primary GC single-cell atlas to resolve malignant cell states linked to prognosis and to identify candidate targets. Single-cell transcriptomes from tumor, adjacent/normal, and premalignant gastric tissues were integrated. After quality control and doublet removal, data were batch-corrected, clustered, and annotated. Malignant epithelial cells were inferred from large-scale copy-number variation patterns and re-clustered. A prognostic signature was constructed by using the top marker genes of the low-differentiation ARHGDIB⁺ malignant epithelial state as a biologically informed candidate pool, followed by univariable Cox regression and LASSO Cox modeling in the TCGA stomach adenocarcinoma cohort. Survival was evaluated by Kaplan-Meier analysis with log-rank testing, and discrimination was assessed by time-dependent receiver operating characteristic analysis. Immune context was estimated by computational deconvolution and Tumor Immune Dysfunction and Exclusion scoring. Cell-cell communication was inferred from ligand-receptor expression. EMB expression across GC cell lines was assessed using CCLE/DepMap data, and EMB knockdown efficiency was validated by RT-qPCR. EMB function was tested by shRNA knockdown followed by wound-healing and Matrigel Transwell invasion assays and immunoblotting of epithelial-mesenchymal transition markers. Thirteen major cell populations spanning epithelial, immune, and stromal lineages were identified. Copy-number analysis separated malignant from non-malignant epithelium and resolved 8 malignant epithelial clusters. An ARHGDIB+ malignant epithelial state showed the lowest differentiation state and highest stem-like potential. A seven-gene signature stratified patients into high- and low-CSL groups; the high-CSL group had worse overall survival and showed bulk-level immune features consistent with an inflammatory but impaired immune context, including an increased CIBERSORT-estimated M2 macrophage fraction and higher dysfunction/exclusion scores. EMB was prioritized as a candidate prognostic hub gene, and EMB-high cells within the ARHGDIB+ malignant epithelial subcluster showed inferred ligand-receptor interactions with monocytic/macrophage-related immune populations. EMB knockdown reduced gastric cancer cell migration and invasion and shifted epithelial-mesenchymal transition markers, increasing E-cadherin and decreasing N-cadherin. This primary GC single-cell atlas identifies a low-differentiation ARHGDIB⁺ malignant epithelial state and uses its marker genes to derive a seven-gene CSL signature associated with poor prognosis and bulk tumor-level immune features. EMB emerges as a candidate biomarker and functional mediator of GC cell migration and invasion, warranting further mechanistic validation.

PMID 42928163
阅读全文 →
PubMedDiseases (Basel, Switzerland)2026-10-26

The Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Spectrum: A Report of Two Contrasting Cases Managed in a Burn Unit.

Constantinescu Mihai-Codrin MC, Moraru Dan-Cristian DC, Poroch Vladimir V, Avadanei-Luca Stefana S et al.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe, potentially life-threatening mucocutaneous reactions classified based on body surface area (BSA) involvement: SJS affects less than 10% BSA, SJS/TEN overlap affects 10-30% BSA, and TEN affects more than 30% BSA. The mortality rates range from 4.8-9% for SJS to 14.8-48% for TEN. Treatment remains controversial, with corticosteroids and intravenous immunoglobulin (IVIg) being the most debated therapeutic options. While some studies suggest IVIg may block Fas-mediated keratinocyte apoptosis, meta-analyses have shown conflicting results regarding mortality benefit. We describe two patients from opposite ends of the SJS/TEN spectrum, managed in a burn unit with different therapeutic approaches. The first patient, a 47-year-old man with systemic lupus erythematosus, developed TEN with approximately 35% body surface area involvement, complicated by sepsis and rhabdomyolysis; he was treated with systemic corticosteroids and intravenous immunoglobulin (IVIg, 0.4 g/kg/day for 3 days). The second patient, a 66-year-old woman, developed SJS attributed to amoxicillin-clavulanic acid and was treated with systemic corticosteroids alone. Both patients achieved complete re-epithelialization without major sequelae. These two cases illustrate the clinical heterogeneity of the SJS/TEN spectrum and the central role of early recognition, prompt withdrawal of the culprit drug, transfer to a specialized unit, and multidisciplinary supportive care. Given the substantial differences between the two patients in age, sex, comorbidities, culprit drugs, and disease severity, no comparative or causal inference regarding the relative efficacy of the two treatment strategies can be drawn; no efficacy claim is made for either therapeutic approach; this report is descriptive, and the two cases are presented as contrasting rather than comparable.

PMID 42929981
阅读全文 →
PubMedACS applied materials & interfaces2026-10-26

Biomimetic Liquid Diodes Across Materials and Scales for Directional Liquid Transfer.

Sun Yanbo Y, Yang Ling L, Xu Boyuan B, Li Xing X et al.

The last decade has witnessed remarkable advancements in liquid diode, evolving from fundamental research to cutting-edge applications such as microfluidics, thermal management, and wearable electronics. However, how material characteristics and structural scales mediate liquid transport on liquid diodes has yet to be fully clarified to date. In this study, we develop a Crassula muscosa inspired liquid diode (CMLD) with superior material adaptability and structural scale adaptability spanning three orders of magnitude. Such a liquid diode endows a cross-material, and cross-scale unidirectional liquid transfer from microscale to macroscale. The mechanisms underlying the role of the wettability, viscosity and structure scale in regulating the liquid transfer kinetics including transfer distance, transfer velocity and liquid rectification, are clearly demonstrated. By combining experimental observation, numerical simulation, and building a theoretical retention force model, the liquid transfer and pinning mechanisms governed by asymmetric reentrant structures are systematically elucidated, which enables superior robustness for unidirectional liquid transfer of continuous flows with various flow rates. These results provide a robust framework for coupling material characteristics and structural scales to achieve controllable unidirectional liquid transfer, laying a solid foundation for the practical implementation of liquid diode-based technologies.

PMID 42929223
阅读全文 →
PubMedCurrent oncology (Toronto, Ont.)2026-10-26

Clinical and Laboratory Factors Associated with Serious Infections in Multiple Myeloma: A Real-World Study.

Odabaşı Giden Aslı A, Şahin Onur O, Ozatli Duzgun D

Background: Serious infections remain a major cause of morbidity and treatment disruption in patients with multiple myeloma (MM). Identifying readily available clinical factors associated with infectious complications may facilitate risk-adapted supportive care. This study evaluated clinical and laboratory factors associated with serious infection in patients with MM, including the potential association of baseline neutrophil-to-lymphocyte ratio (NLR) with subsequent serious infectious complications. Methods: This retrospective multicenter cohort study included 104 patients with MM. Baseline demographic, disease-related, treatment-related, and laboratory characteristics were evaluated. Serious infection was defined as an infectious episode requiring hospitalization. Infectious events were recorded throughout follow-up, including those occurring during second-line and subsequent therapies. Associations with serious infection were assessed using univariate and multivariable binary logistic regression analyses. The primary multivariable model included age, International Staging System (ISS) stage, dialysis requirement at diagnosis, treatment response, and baseline NLR. Results: Serious infections occurred in 39 patients (37.5%). Dialysis requirement at diagnosis (30.8% vs. 4.6%, p = 0.001), failure to achieve treatment response (51.3% vs. 7.7%, p < 0.001), hypogammaglobulinemia (48.7% vs. 29.2%, p = 0.046), and IVIG administration (76.9% vs. 46.2%, p = 0.002) were more frequent among patients with serious infection. Baseline NLR did not differ significantly between patients with and without serious infection. In the multivariable model, dialysis requirement at diagnosis (adjusted OR 8.26, 95% CI 1.81-37.68; p = 0.006) and failure to achieve treatment response (adjusted OR 16.77, 95% CI 4.37-64.31; p < 0.001) were independently associated with serious infection, whereas age, ISS stage, and baseline NLR were not. Conclusions: Serious infections were common in this real-world MM cohort. Dialysis requirement at diagnosis and failure to achieve treatment response were independently associated with serious infection, whereas baseline NLR was not independently associated with serious infectious complications. These findings suggest that clinical characteristics reflecting renal dysfunction and treatment response may be useful for identifying patients at increased risk of serious infection. The observed association between IVIG administration and serious infection should be interpreted cautiously because of potential confounding by indication and reverse causality.

PMID 42930182
阅读全文 →
PubMedCureus2026-10-26

Bilateral Earlobe Purpura as an Unusual Initial Manifestation of Systemic Lupus Erythematosus: A Case Report.

Atherton Lucy L

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by autoantibody production, particularly antinuclear antibodies (ANAs). The broad clinical spectrum and absence of pathognomonic features can make diagnosis challenging, particularly when alternative autoimmune, infectious, and hematological conditions must be considered. We report a case of a 31-year-old woman who presented to the emergency department with a two-week history of bilateral earlobe purpura. Initial investigations demonstrated severe thrombocytopenia and normocytic anemia, and subsequent imaging revealed widespread lymphadenopathy. Early multidisciplinary assessment by acute medicine, hematology, and rheumatology, together with exclusion of hematological malignancy and positive autoimmune serology, supported a diagnosis of SLE. Despite initial treatment with intravenous immunoglobulin (IVIg) and corticosteroids, the bicytopenia persisted. Mycophenolate mofetil was commenced; however, worsening cytopenias and concern for secondary hemophagocytic lymphohistiocytosis led to the initiation of rituximab infusions. Her platelet count subsequently improved, and she was discharged with rheumatology and hematology follow-up. This case highlights an unusual cutaneous presentation of newly diagnosed SLE and the diagnostic challenges associated with severe hematological involvement at initial presentation. It also demonstrates the importance of multidisciplinary assessment and timely escalation of immunosuppressive therapy in severe disease.

PMID 42928827
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多IVIG